Analysts have a consensus target price of $ 47.33 in the 12-month period. The price objective is 16.29% higher than the recent closing price of $ 40.70. The 52-week price range is $ 35.58 – 45.10 and the company has a market capitalization of $ 98.46B. Analysts covering the shares maintain a consensus Buy rating, according to Zacks Investment Research. 1 analyst has rated the stock with a sell rating, 4 has assigned a hold rating, zero says it’s a buy, and 2 have assigned a strong buy rating to the company.
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company operates through five segments: Global Pharmaceuticals, HIV, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. The company also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas under the Sensodyne, Horlicks, Parodontax, Poligrip, Voltaren, Panadol, Otrivin, Tums, Flonase, Eno, and Theraflu brand names. GlaxoSmithKline plc offers its consumer healthcare products in the form of tablets, caplets, infant syrup drops, topical gels, nasal sprays, effervescents, lozenges, gum and trans-dermal patches, malted drinks and foods, and creams. The company has a strategic collaboration with Miltenyi Biotec GmbH to develop a cell and gene therapy automation and processing technology. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
0 yorum:
Yorum Gönder